Results 211 to 220 of about 631,065 (281)

The Pathway to Proof‐of‐Concept for BNC210, a Negative Allosteric Modulator of the Alpha‐7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract BNC210 is an investigational small molecule selective negative allosteric modulator of the alpha‐7 nicotinic acetylcholine receptor (α7 nAChR). It is an anxiolytic compound with a novel mechanism of action. In a series of Phase 1 clinical trials in healthy volunteers, psychometric test batteries showed that BNC210 did not cause attention ...
Paul Rolan   +7 more
wiley   +1 more source

Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox–Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti‐seizure medication (ASM).
Andriy A. Gorbenko   +7 more
wiley   +1 more source

System edukacji w zakresie nauk przyrodniczych a IBSE (inquiry-based science education)

open access: yesStudia Etnologiczne i Antropologiczne, 2017
Magda Żołubak
doaj  

Home - About - Disclaimer - Privacy